Beeline Medicines Corporation launches Phase 2/3 trial for lupus drug in Stamford
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Beeline Medicines Corporation announced the start of a global Phase 2/3 DISCOVERY trial for afimetoran in Stamford. The trial is designed to evaluate the efficacy and safety of afimetoran compared to placebo in adults with active cutaneous lupus erythematosus, with or without systemic lupus. Afimetoran is an investigational oral inhibitor of Toll-like receptors 7 and 8.
From manilatimes.net
Why it matters
The DISCOVERY trial is a pivotal program for afimetoran, which targets key drivers of lupus biology. Successful results from this study could advance the drug toward treating autoimmune and inflammatory diseases.
From manilatimes.net
Who's involved
Keep exploring
The entities involved
-
Stamford
city in Fairfield County, Connecticut, United States
Nothing else this week.